journal article·2025-01Open access

Mechanical Activation of cPLA2 Impedes Fatty Acid β‐Oxidation in Vein Grafts

Linwei Fan, Yuanjun Tang, Jian Liu, Yueqi Liu, Yiwei Xu, Jiayu Liu, Han Liu, Wei Pang, Yuxuan Guo, Weijuan Yao, Tao Zhang, Qin Peng, Jing Zhou

Advanced Science· Volume 12· Issue 3

Abstract

Abstract High‐magnitude cyclic stretch from arterial blood pressure significantly contributes to the excessive proliferation and migration of vascular smooth muscle cells (VSMCs), leading to neointima formation in vein grafts. However, the molecular mechanisms remain unclear. This study highlights the critical role of cytosolic Phospholipase A2 (cPLA2)/ Yin Yang 1 (YY1)/ carnitine palmitoyltransferase 1b (CPT1B) signaling in coordinating VSMC mechanical activation by inhibiting fatty acid β‐oxidation. Metabolomic analysis showed that a 15%–1 Hz arterial cyclic stretch, compared to a 5%–1 Hz venous stretch, increased long‐chain fatty acids in VSMCs. cPLA2, identified as a mechanoresponsive molecule, produces excessive arachidonic acid (ArAc) under the 15%–1 Hz stretch, inhibiting CPT1B expression, a key enzyme in fatty acid β‐oxidation. ArAc promotes transcription factor YY1 degradation, downregulating CPT1B. Inadequate fatty acid oxidation caused by knockdown of CPT1B or YY1, or etomoxir treatment, increased nuclear membrane tension, orchestrating the activation of cPLA2. Overexpressing CPT1B or inhibiting cPLA2 reduced VSMC proliferation and migration in vein grafts, decreasing neointimal hyperplasia. This study uncovers a novel mechanism in lipid metabolic reprogramming in vein grafts, suggesting a new therapeutic target for vein graft hyperplasia.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Cardiac Valve Diseases and Treatments · Peroxisome Proliferator-Activated Receptors · Lipoproteins and Cardiovascular Health

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Physiology and Pathophysiology School of Basic Medical Sciences State Key Laboratory of Vascular Homeostasis and Remodeling Department of Cardiology and Institute of Vascular Medicine Peking University Third Hospital National Health Commission Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides Beijing Key Laboratory of Cardiovascular Receptors Research Peking University Beijing 100191 China

Shenzhen Bay Laboratory Shenzhen 518132 China

Institute of Cardiovascular Sciences School of Basic Medical Sciences State Key Laboratory of Vascular Homeostasis and Remodeling Beijing Key Laboratory of Cardiovascular Receptors Research Peking University Beijing 100191 China

Department of Vascular Surgery Peking University People's Hospital Beijing 100044 China

Funding

National Natural Science Foundation of China · Key Technologies Research and Development Program

References (75)

Show source-provided references
1. 10.1016/S0140-6736(19)31997-X10.1016/S0140-6736(19)31997-X ↗
2. Campeau L. · Circulation · 1983 · 68 · II1
3. Yazdani S. K. · Interv. Cardiol. Clin. · 2013 · 2 · 241
4. 10.1161/CIRCULATIONAHA.120.05216310.1161/CIRCULATIONAHA.120.052163 ↗
5. 10.1161/01.RES.0000037090.34760.EE10.1161/01.RES.0000037090.34760.EE ↗
6. 10.1016/j.jvs.2009.07.10210.1016/j.jvs.2009.07.102 ↗
7. 10.1038/s41569-019-0249-310.1038/s41569-019-0249-3 ↗
8. 10.1161/01.HYP.26.1.210.1161/01.HYP.26.1.2 ↗
9. 10.1093/cvr/cvy02110.1093/cvr/cvy021 ↗
10. 10.1073/pnas.221963012010.1073/pnas.2219630120 ↗
11. Tang Y. · Circ. Res. · 2022 · 130 · 26
12. 10.1161/ATVBAHA.121.31602110.1161/ATVBAHA.121.316021 ↗
13. 10.1161/CIRCULATIONAHA.120.05117110.1161/CIRCULATIONAHA.120.051171 ↗
14. 10.1161/CIRCRESAHA.122.32100510.1161/CIRCRESAHA.122.321005 ↗
15. 10.1146/annurev.physiol.64.082201.15470510.1146/annurev.physiol.64.082201.154705 ↗
16. 10.1126/scitranslmed.aao030310.1126/scitranslmed.aao0303 ↗
17. 10.1016/j.fct.2022.11354610.1016/j.fct.2022.113546 ↗
18. 10.1016/j.jhep.2017.11.01410.1016/j.jhep.2017.11.014 ↗
19. Li X. · Nature · 2023 · 622 · 619
20. 10.1161/ATVBAHA.113.30209910.1161/ATVBAHA.113.302099 ↗
21. 10.1126/scitranslmed.300132710.1126/scitranslmed.3001327 ↗
22. 10.1183/13993003.04252-202010.1183/13993003.04252-2020 ↗
23. 10.1038/s41556-018-0038-y10.1038/s41556-018-0038-y ↗
24. 10.1083/jcb.20161004210.1083/jcb.201610042 ↗
25. 10.1016/j.ceb.2019.02.01210.1016/j.ceb.2019.02.012 ↗
26. 10.1038/s41580-022-00480-z10.1038/s41580-022-00480-z ↗
27. 10.1016/j.pharmthera.2023.10838210.1016/j.pharmthera.2023.108382 ↗
28. 10.1016/j.cell.2016.04.01610.1016/j.cell.2016.04.016 ↗
29. 10.1126/science.aba289410.1126/science.aba2894 ↗
30. 10.1046/j.1444-2892.2002.00138.x10.1046/j.1444-2892.2002.00138.x ↗
31. 10.1053/j.ajkd.2018.12.03510.1053/j.ajkd.2018.12.035 ↗
32. 10.1016/j.jss.2014.01.04210.1016/j.jss.2014.01.042 ↗
33. 10.1016/j.mam.2004.06.00410.1016/j.mam.2004.06.004 ↗
34. 10.1161/CIRCRESAHA.110.22258810.1161/CIRCRESAHA.110.222588 ↗
35. 10.1073/pnas.160456911310.1073/pnas.1604569113 ↗
36. 10.1038/s41598-020-58334-710.1038/s41598-020-58334-7 ↗
37. 10.1016/j.redox.2022.10258610.1016/j.redox.2022.102586 ↗
38. 10.1038/nrc348310.1038/nrc3483 ↗
39. 10.1089/ars.2021.015710.1089/ars.2021.0157 ↗
40. 10.1016/j.redox.2019.10128410.1016/j.redox.2019.101284 ↗
41. 10.1002/ejhf.132010.1002/ejhf.1320 ↗
42. Liu J. · bioRxiv · 2024
43. 10.1073/pnas.211239011910.1073/pnas.2112390119 ↗
44. 10.1083/jcb.20180405210.1083/jcb.201804052 ↗
45. 10.1016/S0022-2275(20)41084-310.1016/S0022-2275(20)41084-3 ↗
46. 10.1016/j.bbalip.2007.01.01610.1016/j.bbalip.2007.01.016 ↗
47. 10.1007/s00253-019-10002-110.1007/s00253-019-10002-1 ↗
48. 10.1093/eurheartj/ehy39410.1093/eurheartj/ehy394 ↗
49. 10.1111/j.1440-1711.2005.01407.x10.1111/j.1440-1711.2005.01407.x ↗
50. 10.1161/ATVBAHA.107.14737110.1161/ATVBAHA.107.147371 ↗
51. 10.1111/j.1365-2796.2006.01624.x10.1111/j.1365-2796.2006.01624.x ↗
52. 10.1042/CS2008016310.1042/CS20080163 ↗
53. 10.2174/092986704336532310.2174/0929867043365323 ↗
54. 10.1111/j.1523-1755.2004.00405.x10.1111/j.1523-1755.2004.00405.x ↗
55. 10.1016/j.bbalip.2010.12.00710.1016/j.bbalip.2010.12.007 ↗
56. 10.1002/advs.20220399510.1002/advs.202203995 ↗
57. 10.1186/s12931-024-02775-510.1186/s12931-024-02775-5 ↗
58. 10.1016/j.redox.2013.10.01110.1016/j.redox.2013.10.011 ↗
59. 10.1016/j.cmet.2018.07.01610.1016/j.cmet.2018.07.016 ↗
60. 10.1016/j.celrep.2017.08.02910.1016/j.celrep.2017.08.029 ↗
61. 10.1002/advs.20230868610.1002/advs.202308686 ↗
62. 10.3390/antiox1104064310.3390/antiox11040643 ↗
63. 10.1152/ajplung.2001.281.5.L105810.1152/ajplung.2001.281.5.L1058 ↗
64. 10.1016/j.cardiores.2006.02.03310.1016/j.cardiores.2006.02.033 ↗
65. 10.1089/ars.2009.287510.1089/ars.2009.2875 ↗
66. 10.1093/cvr/cvab02110.1093/cvr/cvab021 ↗
67. 10.1016/j.jbior.2017.10.00810.1016/j.jbior.2017.10.008 ↗
68. 10.1016/j.bbamem.2017.04.00610.1016/j.bbamem.2017.04.006 ↗
69. 10.1016/j.jaac.2011.06.00810.1016/j.jaac.2011.06.008 ↗
70. 10.1016/S0378-1119(99)00261-910.1016/S0378-1119(99)00261-9 ↗
71. 10.1111/cpr.1232210.1111/cpr.12322 ↗
72. 10.1055/s-0037-160745110.1055/s-0037-1607451 ↗
73. 10.1210/me.2013-117310.1210/me.2013-1173 ↗
74. 10.1016/j.bbamcr.2014.04.02310.1016/j.bbamcr.2014.04.023 ↗
75. 10.1016/j.bbrc.2013.08.08210.1016/j.bbrc.2013.08.082 ↗